Cancer Genetics, Inc. Partners with Ventana Medical Systems, Inc., a member of the Roche Group, to Ensure Market Access to Predictive Biomarker Test for New Immuno-Oncology (IO) Therapy for Advanced Bladder Cancer
May 15, 2017 07:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., May 15, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in precision diagnostics for oncology, announced today that it has partnered...
Cancer Genetics, Inc. Announces 15% Revenue Increase in First Quarter of 2017 over 2016 on Strong Organic Growth While Continuing on Path to Profitability
May 11, 2017 18:23 ET
|
Cancer Genetics, Inc.
Revenue increased to $7.0 million in Q1 2017, up 15% compared to Q1 2016 on strong organic growthTest volumes increased 19% year-over-year to 12,310Gross profit margin was 40%, up from 32% for Q1...
Cancer Genetics, Inc. Changes The Paradigm For Lung Cancer Monitoring – Launches Clinically Actionable, Multi-Gene, Liquid Biopsy Test For Lung Cancer Patients, Liquid::Lung-cfDNA™
May 08, 2017 07:32 ET
|
Cancer Genetics, Inc.
CGI has launched the multi-gene, next-generation sequencing (NGS) panel with CLIA validation, and will perform the test for both clinical care and for trials being performed by biotech and...
Cancer Genetics to Hold First Quarter 2017 Earnings Call on Friday, May 12th
May 05, 2017 08:48 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., May 05, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today...
Cancer Genetics, Inc. to Present at The Pioneers 2017 Conference Presented by Joseph Gunnar & Co., LLC
April 25, 2017 07:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., April 25, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and...
Cancer Genetics, Inc. Launches a Unique, Industry-Leading Panel That Provides Comprehensive & Precise Information for Immuno-Oncology Therapy Assessment & Patient Monitoring
April 24, 2017 07:19 ET
|
Cancer Genetics, Inc.
Complete::IOTM provides immune endpoint and immune monitoring of patients allowing informed therapeutic decisions and assessment of potential toxicities of IO therapies in blood cancers and solid...
Cancer Genetics, Inc. is Selected by eFFECTOR Therapeutics to Provide Biomarker Discovery and Development Services for Novel Oncology Drugs
April 10, 2017 07:00 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J. and SAN DIEGO, April 10, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through...
Cancer Genetics, Inc. and Mendel.ai Announce Strategic Partnership Enabling Artificial Intelligence in Precision Medicine to Drive Personalized Treatment and Accelerate Clinical Trial Matching for Cancer Care
April 03, 2017 07:00 ET
|
Cancer Genetics, Inc.
Powerful New Capability Leverages Artificial Intelligence & Big Data Analytics to Accelerate and Democratize Access to Clinical Trials for CancerCGI and Mendel.ai will be Among the First in...
Cancer Genetics, Inc. to Present at The MicroCap Conference on April 4th at 08:00 AM in New York City
March 28, 2017 16:10 ET
|
Cancer Genetics, Inc.
RUTHERFORD, N.J., March 28, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced...
Cancer Genetics, Inc. Announces Record Revenue for Fourth Quarter and Full-Year 2016 and Provides 2017 Business Update
March 23, 2017 07:30 ET
|
Cancer Genetics, Inc.
Full-year 2016 revenues up 50% year-over-year to $27 million from $18 millionFourth quarter revenues up 32% year-over-year on strong organic growth to $7.2 millionFourth quarter gross profit margins...